{"id":1060,"date":"2019-08-12T07:30:26","date_gmt":"2019-08-12T06:30:26","guid":{"rendered":"https:\/\/www.competitionlawyers.co.uk\/blog\/?p=1060"},"modified":"2019-08-07T14:30:34","modified_gmt":"2019-08-07T13:30:34","slug":"anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued","status":"publish","type":"post","link":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued","title":{"rendered":"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued"},"content":{"rendered":"

In the latest investigation into suspected anti-competitive agreements for pharmaceutical drugs, a statement of objections has been issued by the CMA (Competition and Markets Authority).<\/p>\n

The statement was issued last month and relates to a number of pharmaceutical companies who stand accused of participating in anti-competitive behaviour. Whether it\u2019s a case of formal agreements in place, or concerted practices, the issue surrounds the supply of 50mg and 100mg nitrofurantoin capsules in the UK.<\/p>\n

This investigation by the CMA into the practices of pharmaceutical firms is one of many that have been ongoing for a number of years. They\u2019re one of the most important areas the CMA needs to safeguard.<\/p>\n

<\/p>\n

Latest suspected anti-competitive agreements for pharmaceutical drugs<\/strong><\/h3>\n

In the latest news of investigations into suspected anti-competitive agreements for pharmaceutical drugs, a number of firms are under the microscope.<\/p>\n

The statement of objections issued alleges that at least two suppliers of nitrofurantoin and a wholesaler engaged in anti-competitive behaviour between 2014 and 2017. The alleged arrangement is said to have involved Alliance Healthcare agreeing to buy equal volumes of drugs from two suppliers, AMCo (now Advanz) and Morningside.<\/p>\n

There was also said to be an exclusivity arrangement in 2015 and 2016 whereby they would only supply to Alliance.<\/p>\n

The importance of this investigation<\/strong><\/h3>\n

This particular investigation into suspected anti-competitive agreements for pharmaceutical drugs involves another important prescription-only medicine.<\/p>\n

This means that, where prices are inflated by breaches of important competition law<\/strong><\/a>, \u00a0it\u2019s our NHS – i.e. the taxpayer – that\u2019s picking up the bill to line the pockets of big pharmaceutical corporations.<\/p>\n

This kind of behaviour isn\u2019t fair, and it\u2019s completely immoral!<\/p>\n

If the suspicions of the alleged behaviour are found to be true, the companies involved deserve significant financial penalties. So far, the CMA has confirmed that they have provisionally found that AMCo allegedly disclosed sensitive pricing information to Morningside with the aim of reducing competition between them.<\/p>\n

What\u2019s being said about the alleged behaviour?<\/strong><\/h3>\n

Comments made by the CMA over the latest investigations into suspected anti-competitive agreements for pharmaceutical drugs are as follows:<\/p>\n

\u201cDrug companies that break competition law risk forcing the NHS, and UK taxpayers, to pay over the odds for important medical treatments.<\/em><\/p>\n

We\u2019ve provisionally found that suppliers of this important antibiotic entered into arrangements with the aim of keeping Nitrofurantoin prices artificially high, meaning the NHS wouldn\u2019t benefit from the lower prices that come from effective competition.\u201d<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

In the latest investigation into suspected anti-competitive agreements for pharmaceutical drugs, a statement of objections has been issued by the CMA (Competition and Markets Authority). The statement was issued last month and relates to a number of pharmaceutical companies who stand accused of participating in anti-competitive behaviour. Whether it\u2019s a case of formal agreements in … Continue reading Anti-competitive agreements for pharmaceutical drugs: statement of objections issued<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":735,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[30,36,8,23],"tags":[2,15,45,35,33,50,9,28],"class_list":["post-1060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-sharing","category-price-fixing","category-price-hikes","category-pricing","tag-cma","tag-competition-law","tag-investigations","tag-market-abuse","tag-marktet-sharing","tag-pharmaceuticals","tag-price-fixing","tag-pricing"],"yoast_head":"\nAnti-competitive agreements for pharmaceutical drugs: statement of objections issued - Competition Lawyers<\/title>\n<meta name=\"description\" content=\"Latest suspected anti-competitive agreements for pharmaceutical drugs; statement of objections issued by the CMA (Competition and Markets Authority)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued - Competition Lawyers\" \/>\n<meta property=\"og:description\" content=\"Latest suspected anti-competitive agreements for pharmaceutical drugs; statement of objections issued by the CMA (Competition and Markets Authority)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued\" \/>\n<meta property=\"og:site_name\" content=\"Competition Lawyers\" \/>\n<meta property=\"article:published_time\" content=\"2019-08-12T06:30:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i1.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2018\/02\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"725\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Matt\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued\"},\"author\":{\"name\":\"Author\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/32c18f906b91fed8634e71af54b2a301\"},\"headline\":\"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued\",\"datePublished\":\"2019-08-12T06:30:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued\"},\"wordCount\":415,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1\",\"keywords\":[\"cma\",\"competition law\",\"investigations\",\"market abuse\",\"marktet sharing\",\"Pharmaceuticals\",\"price fixing\",\"pricing\"],\"articleSection\":[\"Market Sharing\",\"Price Fixing\",\"Price Hikes\",\"Pricing\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued\",\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued\",\"name\":\"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued - Competition Lawyers\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1\",\"datePublished\":\"2019-08-12T06:30:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/32c18f906b91fed8634e71af54b2a301\"},\"description\":\"Latest suspected anti-competitive agreements for pharmaceutical drugs; statement of objections issued by the CMA (Competition and Markets Authority)\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1\",\"width\":725,\"height\":250,\"caption\":\"liothyronine tablets investigation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/\",\"name\":\"Competition Lawyers\",\"description\":\"Latest Legal News, Cases & Articles\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/32c18f906b91fed8634e71af54b2a301\",\"name\":\"Author\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g\",\"caption\":\"Author\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Matt\"],\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/author\\\/matt\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued - Competition Lawyers","description":"Latest suspected anti-competitive agreements for pharmaceutical drugs; statement of objections issued by the CMA (Competition and Markets Authority)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued","og_locale":"en_GB","og_type":"article","og_title":"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued - Competition Lawyers","og_description":"Latest suspected anti-competitive agreements for pharmaceutical drugs; statement of objections issued by the CMA (Competition and Markets Authority)","og_url":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued","og_site_name":"Competition Lawyers","article_published_time":"2019-08-12T06:30:26+00:00","og_image":[{"width":725,"height":250,"url":"https:\/\/i1.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2018\/02\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1","type":"image\/png"}],"author":"Author","twitter_card":"summary_large_image","twitter_creator":"@Matt","twitter_misc":{"Written by":"Author","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#article","isPartOf":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued"},"author":{"name":"Author","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/32c18f906b91fed8634e71af54b2a301"},"headline":"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued","datePublished":"2019-08-12T06:30:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued"},"wordCount":415,"commentCount":0,"image":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2018\/02\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1","keywords":["cma","competition law","investigations","market abuse","marktet sharing","Pharmaceuticals","price fixing","pricing"],"articleSection":["Market Sharing","Price Fixing","Price Hikes","Pricing"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued","url":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued","name":"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued - Competition Lawyers","isPartOf":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#primaryimage"},"image":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2018\/02\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1","datePublished":"2019-08-12T06:30:26+00:00","author":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/32c18f906b91fed8634e71af54b2a301"},"description":"Latest suspected anti-competitive agreements for pharmaceutical drugs; statement of objections issued by the CMA (Competition and Markets Authority)","breadcrumb":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#primaryimage","url":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2018\/02\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2018\/02\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1","width":725,"height":250,"caption":"liothyronine tablets investigation"},{"@type":"BreadcrumbList","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/anti-competitive-agreements-for-pharmaceutical-drugs-statement-of-objections-issued#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.competitionlawyers.co.uk\/blog"},{"@type":"ListItem","position":2,"name":"Anti-competitive agreements for pharmaceutical drugs: statement of objections issued"}]},{"@type":"WebSite","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#website","url":"https:\/\/www.competitionlawyers.co.uk\/blog\/","name":"Competition Lawyers","description":"Latest Legal News, Cases & Articles","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.competitionlawyers.co.uk\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/32c18f906b91fed8634e71af54b2a301","name":"Author","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g","caption":"Author"},"sameAs":["https:\/\/x.com\/Matt"],"url":"https:\/\/www.competitionlawyers.co.uk\/blog\/author\/matt"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2018\/02\/liothyronine-tablets-investigation-min.png?fit=725%2C250&ssl=1","jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=1060"}],"version-history":[{"count":1,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1060\/revisions"}],"predecessor-version":[{"id":1061,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1060\/revisions\/1061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media\/735"}],"wp:attachment":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=1060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=1060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=1060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}